Tag: Fibrosis

Cystic fibrosis is a genetic, progressive disease that causes persistent lung infections and impacts the most basic physical processes. While recent breakthroughs have significantly extended the lifespan of patients with CF, the disease presents patients and their caregivers with significant, lifelong daily challenges. The primary purpose of cystic fibrosis clinics is to treat the physical

Chemical and biomolecular engineer Xue Sherry Gao of Rice University's Brown School of Engineering has won National Institutes of Health support for a new strategy to fight cystic fibrosis. The agency awarded Gao a four-year R01 grant of more than $2 million to adapt tools developed by her lab that increase the accuracy of CRISPR/Cas9-based

Inflammation of the pancreas is referred to as pancreatitis. The pancreas is a flat tadpole-shaped gland located at the back of the stomach in the upper abdomen; it releases certain enzymes and hormones which help in digestion and aids in regulating sugar metabolism in the body. Pancreatitis may manifest in both severe and acute forms.

(HealthDay)—Current and former smokers are at risk for a lung disease called pulmonary fibrosis, but many aren’t aware of the threat, the Pulmonary Fibrosis Foundation says. There is no cure for the disease, which affects more than 200,000 Americans. A recent foundation survey found that more than 80% of smokers are unfamiliar with pulmonary fibrosis.

Scientists have revealed how common respiratory bugs that cause serious infections in people with cystic fibrosis interact together, according to a new study in eLife. The results provide insights into how bacterial pathogens wrestle each other for territory that could open avenues for new antibacterial treatments. Studies of microbes from mouths, intestines, chronic wounds and

An approved drug normally used to treat fungal infections could also do the job of a protein channel that is missing in the lungs of people with cystic fibrosis, operating as a prosthesis on the molecular scale, says new research from the University of Illinois and the University of Iowa. Cystic fibrosis is a lifelong

Schoolboy, 8, is ‘living with a death sentence’ because the NHS won’t fork out for £100,000-per-year cystic fibrosis ‘wonder drug’ George Monckton could be saved from lung deterioration by Orkambi  It could extend the lives of patients who often die before reaching middle age Drug is unavailable on NHS because of a deadlock in price

In an article published online by Frontiers in Endocrinology, researchers at the Medical University of South Carolina (MUSC) report that they have identified a potential therapeutic target for lung fibrosis or scarring. They showed in a preclinical model that the protein promotes fibrosis by turning on profibrotic genes and increasing levels of profibrotic factors, including

The majority of patients with cystic fibrosis may not achieve blood concentrations of antibiotics sufficiently high enough to effectively fight bacteria responsible for pulmonary exacerbations, leading to worsening pulmonary function, indicates a study led by researchers at Children’s National Health System. Additionally, the study findings show that it’s impossible to predict solely from dosing regimens

A new triple-combination drug treatment being trialled at the Mater Hospital in Brisbane could increase the life expectancy of patients with cystic fibrosis. Mater Research Institute-University of Queensland (MRI-UQ) researcher Dr. Lucy Burr said seven patients were enrolled in Phase 2 of the clinical trial, which aimed to treat the underlying cause of cystic fibrosis.

THURSDAY, Oct. 18, 2018 — In what researchers are calling a “breakthrough,” two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis. The trials were short-term, finding that the drug combinations improved adult patients’ lung function over four weeks. But experts said they were

THURSDAY, Aug. 2, 2018 — The C-509T allele in the promoter region of transforming growth factor β (TGFB1) is associated with radiation-induced breast fibrosis risk among patients with early-stage breast cancer, according to study published online July 19 in JAMA Oncology. Aaron J. Grossberg, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center